Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT)

Archives of Internal Medicine

Volumn 162, Issue 22, 2002, Pages 2597-2604

  Rubins, Hanna Bloomfield ^a   Robins, Sander J ^b   Collins, Dorothea ^c   Nelson, David B ^a   Elam, Marshall B ^d   Schaefer, Ernst J ^e   Faas, Fred H ^f   Anderson, James W ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^g LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HAZARD ASSESSMENT; HEART INFARCTION; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COMORBIDITY; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GEMFIBROZIL; GLUCOSE TOLERANCE TEST; HOSPITALS, VETERANS; HUMANS; HYPERINSULINISM; INCIDENCE; INSULIN; MALE; MIDDLE AGED; PROBABILITY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0037049366     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.22.2597     Document Type: Article

References (48)

1. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
2. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. Diabetes Care. 1999;22:233-240.
3. Lakka HM, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: The Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med. 2000;160:1160-1168.
4. Cooper R, Cutler J, Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102:3137-3147.
5. Mokdad A, Bowman B, Ford E, Vinicor F, Marks J, Koplan J. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
6. Cleeman J. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2496.
7. Rubins HB, Robins SJ, Iwane MK, et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol. 1993;71:45-52.
8. Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: Baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol. 1996;78:572-575.
9. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
10. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-508.
11. Meigs JB, Nathan DM, Wilson PW, Cupples A, Singer DE. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance: The Framingham Offspring Study. Ann Intern Med. 1998;128:524-533.
12. Rubins HB, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation. 2001;103:2828-2833.
13. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-825.
14. Robins S, Collins D, Wittes J, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events; VA-HIT: A randomized controlled trial. JAMA. 2001;285:1585-1591.
15. Rauch U, Oscende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences. Ann Intern Med. 2001;134:224-238.
16. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis. 1994;111:161-174.
17. Fujii S, Sobel BE. Direct effects of gemfibrozil on the fibrinolytic system: Diminution of synthesis of plasminogen activator inhibitor type 1. Circulation. 1992;85:1888-1893.
18. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135:447-459.
19. O'Neal D, O'Brien R, Timmins K, et al. Gemfibrozil treatment increases low-density lipoprotein particle size in type 2 diabetes mellitus but does not alter in vitro oxidizability. Diabetic Med. 1998;15:870-877.
20. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
21. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
22. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
23. The Long-term intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
24. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
25. Down JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
26. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 1998;98:2513-2519.
27. Pyorala K, Pedersen T, Kjekshus J, Faergeman O, Olsson A, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care. 2001;20:614-620.
28. Haffner S, Alexander C, Cook T, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med. 1999;159:2661-2667.
29. Sacks F, Tonkin A, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation. 2000;102:1893-1900.
30. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation. 2000;102:21-27.
31. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
32. Elkeles, RS, Diamond J, Poulter C, et al. Cardiovascular outcomes in type 2 diabetes: A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) study. Diabetes Care. 1998;21:641-648.
33. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: Experience from the Helsinki Heart Study. Circulation. 1995;92:1779-1785.
34. Lotufo PA, Gaziano JM, Chae CU, et al. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med. 2001;161:242-247.
35. The DECODE Study Group. Glucose tolerance and cardiovascular mortality. Arch Intern Med. 2001;161:397-404.
36. Perry IJ, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti GM. Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol. 1996;144:224-234.
37. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: A meta-analysis. Circulation. 1998;97:996-1001.
38. Wingard DL, Connor-Barrett E. Is insulin really a heart disease risk factor? Diabetes Care. 1995;18:1299-1304.
39. Fontbonne A, Charles MA, Thilbult N, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15-year follow-up. Diabetologia. 1991;34:356-361.
40. Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality. Diabetes Care. 2000;23:1097-1102.
41. Ferrara A, Connor-Barrett EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: The Rancho Bernardo Study, 1984-1991. Am J Epidemiol. 1994;140:857-867.
42. Welin L, Eriksson H, Larsson B, Ohlson O, Svardsudd K, Tibblin G. Hyperinsulinaemia is not a major coronary risk factor in elderly men: The study of men born in 1913. Diabetologia. 1992;35:766-770.
43. Yarnell JW, Sweenam PM, Marks V, Teale JD, Bolton CH. Insulin in ischaemic heart disease: Are associations explained by triglyceride concentrations? The Caerphilly prospective study. Br Heart J. 1994;71:293-296.
44. Kuusisto J, Mykkamen L, Pyörälä K, Laakso M. Hyperinsulinemic microalbuminuria: A new risk indicator for coronary heart disease. Circulation. 1995;91:831-837.
45. Folsom AR, Szklo M, Stevens J, Liao F, Smith R, Eckfeldt JH. A prospective study of coronary heart disease in relation to fasting insulin, glucose and diabetes. Diabetes Care. 1997;20:935-942.
46. Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
47. Grundy S, Benjamin I, Burke G, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146.
48. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heat disease, I: Prolonged differences in blood pressure: Prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.